Kehan Xu, PHD, MBA
Pyxis Blue Alpha – Co-Founder & Chair of Investment Engine
Dr. Kehan Xu is an Adjunct Associate Professor at The Chinese University of Hong Kong. Dr. Xu’s research focuses on marketing-finance interface, entrepreneurship, and portfolio strategy (long/short equity, bond, & international) of innovative industries. Dr. Xu has published in scholarly journals such as Journal of Management Accounting Research, Journal of Management, and Academy of Management Perspectives. Dr. Xu presents cutting-edge research findings based on quantitative models in American Marketing Association annual conferences (2019 –2021) for topics of product innovation, brand disposal and acquisition, and short-selling. Kehan Xu received his PhD from the Mays Business School at Texas A&M University, and his MBA in investments from the University of Miami.
Dr. Xu is the co-founder of Dawnrays Biotech Capital (Asia) Limited, which focuses on innovative monoclonal antibody (mAb) projects and clinical studies. Before embarking on his academic endeavor, Dr. Xu served as the Executive Director and Chief Financial Officer of Dawnrays Pharmaceutical (Holdings) Limited (2348 HK) and Executive Vice President and Chief Financial Officer of Sing Lee Software (Group) Limited (8076 HK), both of them IPOed in the Hong Kong Stock Exchange.